Advanced Search

 

Study ID Status Title Patient Level Data
113109 Completed A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg once daily Compared with Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg twice daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
113120 Completed Safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of GSK573719 and GW642444 in subjects with COPD Study Listed on ClinicalStudyDataRequest.com
113121 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
113124 Completed An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects with Ovarian Cancer
113125 Completed A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of Dolutegravir in Subjects with Renal Impairment and Healthy Matched Control Subjects (ING113125)
113126 Completed A randomised, double-blind, placebo-controlled, four-way crossover, repeat dose study comparing the effect of inhaled fluticasone furoate/GW642444M combination, GW642444M and fluticasone furoate on the allergen-induced asthmatic response in subjects with mild asthma Study Listed on ClinicalStudyDataRequest.com
113132 Completed A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263 Study Listed on ClinicalStudyDataRequest.com
113134 Completed Study of maternal-foetal cytomegalovirus (CMV) transmission
113140 Completed A Randomized, Double-Blind, Placebo-Controlled, Phase I Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered as Single and Multiple Doses in the Fed State to Normal Healthy Male Volunteers Study Listed on ClinicalStudyDataRequest.com
113147 Completed A randomised double-blind, placebo controlled, parallel group study to evaluate the cognitive enhancing effect of GSK239512 in stable patients with schizophrenia Study Listed on ClinicalStudyDataRequest.com
113149 Completed Pharmacovigilence for retapamulin: Age-stratified monitoring of prescribed use in the European Union
113151 Completed Primary vaccination course with the pneumococcal vaccine GSK 1024850A, in healthy infants in Vietnam when co-administered with GSK Biologicals’ Infanrix hexa™ (DTPa-HBV-IPV/Hib) vaccine Study Listed on ClinicalStudyDataRequest.com
113153 Completed Liver Function Test (LFT) elevations in cancer patients and users of tyrosine kinase inhibitor (TKI) drugs using the LabRx Database
113158 Completed Pharmacovigilence for Retapamulin: Age-stratified monitoring of prescribed use in the United States
113160 Completed A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects Study Listed on ClinicalStudyDataRequest.com
113161 Completed A randomised, double-blind, placebo-controlled, multi-way crossover study to assess the effects of single oral doses of SRT2104 and prednisolone on biomarkers in blood in healthy volunteers Study Listed on ClinicalStudyDataRequest.com
113164 Completed Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery
113165 Completed A study to evaluate the safety and immunogenicity of a booster dose of GSK Biologicals’ HIV candidate vaccine (732461) after administration of chloroquine in healthy adults.
113166 Completed Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Malian children Study Listed on ClinicalStudyDataRequest.com
113171 Completed Safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen in children aged 12-23 months at the time of first vaccination. Study Listed on ClinicalStudyDataRequest.com
113172 Terminated Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic combined with standard neoadjuvant treatment in patients with WT1-positive primary invasive breast cancer
113173 Completed Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in patients with metastatic melanoma
113174 Terminated Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in patients with resectable Non-Small Cell Lung Cancer
113191 Completed A Human Phase 0, Microdose Drug-Drug Interaction Study with [14C]-GSK706769 and Ketoconazole in Healthy Male Volunteers
113199 Completed Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Nigerian children Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.